Quantcast
Last updated on April 17, 2014 at 13:43 EDT

Latest Sequenom Stories

2012-09-12 02:30:16

SAN DIEGO, Sept. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the pricing of its offering of $110.0 million aggregate principal amount of Convertible Senior Notes due 2017 (the "Convertible Notes") in a private offering. The sale of the Convertible Notes is expected to close on September 17, 2012, subject to customary closing conditions. Sequenom also granted to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $20.0...

2012-09-12 02:29:28

SAN DIEGO, Sept. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Lazard Capital Markets Corporate Access Day in Boston, Mass., and the Credit Suisse 3(rd) Annual Small and Mid-Cap Conference, in New York. On Tuesday, September 18, Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will participate in the Lazard...

2012-09-10 10:26:53

SAN DIEGO, Sept. 10, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced that it intends to offer, subject to market and other considerations, $100.0 million aggregate principal amount of Convertible Senior Notes due 2017 (the "Convertible Notes") in a private offering. Sequenom also intends to grant to the initial purchasers of the Convertible Notes a 30-day option to purchase up to an additional $20.0 million aggregate principal amount of the Convertible Notes solely to...

2012-09-05 02:31:21

SAN DIEGO, Sept. 5, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Morgan Stanley Global Healthcare Conference, September 10-12, 2012 at the Grand Hyatt in New York. Paul V. Maier, Chief Financial Officer, will present on Wednesday, September 12, 2012, beginning at 9:10 a.m. ET, to provide an overview of and update on the Company. The...

2012-09-04 02:28:36

SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the appointment of Myla Lai-Goldman, M.D., to its Board of Directors, effective September 11, 2012. Dr. Lai-Goldman has also been appointed to the Science Committee of the Company's Board of Directors. Dr. Lai-Goldman is a managing partner at Personalized Science, LLC, and Chief Executive Officer of GeneCentric...

2012-08-28 02:28:06

SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that its wholly-owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), has completed several international distribution agreements that will expand access to the MaterniT21 PLUS testing service outside the United States. Agreements in Asia cover Japan and Hong Kong; in Europe cover the...

2012-08-20 02:29:22

SAN DIEGO, Aug. 20, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that its European licensing partner, LifeCodexx, is launching its PraenaTest® service in more than 70 prenatal clinics and hospitals in Germany, Austria, Liechtenstein and Switzerland. This follows receipt of a CE Mark, a regulatory approval allowing LifeCodexx to market the test. "Based on our licensing...

2012-08-08 10:25:48

SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Wedbush PacGrow Lifesciences Management Access Conference, August 14-15, 2012 at the Le Parker Meridien Hotel in New York, NY. Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will present on Tuesday, August 14, 2012, beginning at 8:35 a.m. ET, to...

2012-07-26 10:27:23

SAN DIEGO, July 26, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $18.3 million for the second quarter of 2012, an increase of 23% from revenue of $14.9 million in the first quarter of 2012 and a 38% increase compared to revenue of $13.3 million for the second quarter of 2011. Second quarter 2012 revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostic services...

2012-07-16 14:20:53

SAN DIEGO, July 16, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has filed a Notice of Appeal to the U.S. Court of Appeals for the Federal Circuit from the July 5, 2012 Preliminary Injunction Order of the U.S. District Court for the Northern District of California denying Sequenom's request for preliminary injunctive relief. Sequenom had previously requested that the district court enjoin...